The Relationship Between Diabetes Mellitus and Parkinson'S Disease

References

• Aronson S. M. Intracranial vascular lesions in patients with diabetes mellitus. Journal of Neuropathology and Experimental Neurology 1973; 32: 183–196
   PubMed Web of Science ®Google Scholar
• Barbeau A. Experience clinique avec le tolbutamide dans la maladie de Parkinson. Union Medicale Canada 1961; 90: 147–151
   PubMedGoogle Scholar
• Barbeau A., Pourcher E. Genetics of early onset Parkinson's disease. Current concepts of parkinson disease and related disorders, M. D. Yahr. Excerpta Medica., Amsterdam 1983
   Google Scholar
• Bitar M., Koulu M., Rapoport S. I., Linnoila M. Diabetes-induced alteration in brain monoamine metabolism in rats. Journal of Pharmacology and Experimental Therapeutics 1986; 236: 432–437
   PubMed Web of Science ®Google Scholar
• Boyd A. E., Lebovitz H. F., Feldman J. M. Endocrine function and glucose metabolism in patients with Parkinson's disease and their alteration by L-dopa. Journal of Clinical Endocrinology and Metabolism 1971; 33: 829–837
   PubMed Web of Science ®Google Scholar
• Burt D. R., Creese I., Snyder S. H. Anti-schizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 1977; 196: 336–328
   PubMedGoogle Scholar
• Campbell B. A., Fibiger H. C. Potentiation of amphetamine-induced arousal by starvation. Nature 1971; 233: 424–425
   PubMedGoogle Scholar
• Chu P. C., Lin M. T., Shian L. R., Leu S. Y. Alterations in physiologic functions and in brain monoamine content in streptozocin-diabetic rats. Diabetes 1986; 35: 481–485
   PubMed Web of Science ®Google Scholar
• Creese I., Iversen S. D. The role of forebrain dopamine systems in amphetamine induced stereotyped behavior in the rat. Psychopharmacology 1974; 39: 345–347
   PubMedGoogle Scholar
• El'ner A. M., Kandel E. I. Study of the carbohydrate metabolism in Parkinsonism. ZH Nervopatol Psikhiat IM SS Korsakova 1965; 65: 46–50
   PubMedGoogle Scholar
• Ganzini L., Heintz R. T., Hoffman W. F., Casey D. E. The prevalence of tardive dys kinesia in neuroleptic-treated diabetics. Archives of General Psychiatry 1991; 48: 250–263
   Google Scholar
• Hakanson R., Lundquist I., Rerup C. On the hyperglycemic effect of dopa and dopamine. European Journal of Pharmacology 1967; 1: 114–119
   PubMedGoogle Scholar
• Hayashi T., Asakuma K., Fujimoto S. Studies on dopa and dopamine hyperglycemia. Bulletin of Osaka Medical School 1968; 14: 134–145
   PubMedGoogle Scholar
• Hirano A., Zimmerman H. M. Alzheimer's neurofibrillary changes. Archives of Neurology 1962; 7: 227–242
   PubMedGoogle Scholar
• Jellinger K. Overview of morphological changes in Parkinson's disease. Advances in Neurology 1986; 45: 1–18
   Google Scholar
• Johnson P. C., Brendel K., Meezan E. Thickened cerebral cortical capillary basement membranes in diabetes. Archives of Pathology and Laboratory Medicine 1982; 106: 214–217
   PubMed Web of Science ®Google Scholar
• Karam J. H. Diabetes mellitus, hypoglycemia, & Lipoprotein disorders. Current medical diagnosis & treatment, S. A. Schroeder, M. A. Krupp, L. M. Tierney, S. J. McPhee. Appleton & Lange., Norwalk 1989; 787–821
   Google Scholar
• Kelley P. H., Seviour P. W., Iversen S. D. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Research 1975; 94: 507–522
   PubMedGoogle Scholar
• Klawans H. L. The pharmacology of tardive dyskinesia. American Journal of Psychiatry 1973; 130: 82–86
   PubMed Web of Science ®Google Scholar
• Klawans H. L. Levodopa-induced dyskinesias. Parkinson's disease, G. Stern. Chapman and Hall Medical., London 1990; 537–557
   Google Scholar
• Klawans H. L., Weiner W. J. Textbook of clinical neuropharmacology. Raven Press., New York 1981
   Google Scholar
• Lackovic Z., Salkovic M., Kuchi Z. Effect of long-lasting diabetes mellitus on rat and human brain monoamines. Journal of Neurochemistry 1990; 54: 143–147
   PubMed Web of Science ®Google Scholar
• Langston J. W., Forno L. S. The hypothalamus in Parkinson disease. Annals of Neurology 1978; 3: 129–133
   PubMed Web of Science ®Google Scholar
• Lipman I. J., Boykin M. E., Flora R. E. Glucose intolerance in Parkinson's disease. Journal of Chronic Disease 1974; 27: 573–579
   PubMedGoogle Scholar
• Locke S., Tarsy D. The nervous system and diabetes. Joslin's diabetes mellitus, A. Marble, L. P. Krall, R. F. Bradly, A. R. Christlieb, J. S. Soeldner. Lea & Fibiger., Philadelphia 1985; 665–686
   Google Scholar
• Lozovsky D., Saller C. F., Kopin I. J. Dopamine receptor binding is increased in diabetic rats. Science 1981; 214: 1031–1032
   PubMed Web of Science ®Google Scholar
• Malarkey W. B., Cyrus J., Paulson G. W. Dissociation of growth hormone and prolactin secretion in Parkinson's disease following chronic L-dopa therapy. Journal of Clinical Endocrinology & Metabolism 1974; 3: 229–235
   Google Scholar
• Marshall J. F. Further analysis of the resistance of the diabetic rat to d-amphetamine. Pharmacology Biochemistry & Behavior 1978; 8: 281–286
   PubMedGoogle Scholar
• Marshall J. F., Friedman M. I., Heffner T. G. Reduced anorexic and locomotor-stimulant action of d-amphetamine in alloxan-diabetic rats. Brain Research 1976; 111: 428–432
   PubMedGoogle Scholar
• McCaleb M. I., Myers R. D. Striatal dopamine release is altered by glucose and insulin during push-pull perfusion of the rat's caudate nucleus. Brain Research Bulletin 1979; 4: 651–656
   PubMedGoogle Scholar
• Montefusco O., Assini M. C., Missale C. Insulin-mediated effects of glucose on dopamine metabolism. Acta Diabetologica Latinica 1983; 20: 71–77
   PubMedGoogle Scholar
• Mukherjee S., Wisniewski A., Bilder R. Possible association between tardive dyskinesia and altered carbohydrate metabolism. Archives of General Psychiatry 1985; 42: 205
   PubMedGoogle Scholar
• Mukherjee S., Roth S., Sandyk R. Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance. Psychiatry Research 1989; 29: 17–27
   PubMed Web of Science ®Google Scholar
• Murrow R. W., Schweiger G. D., Kepes J. J., Koller W. C. Parkinsonism due to basal ganglia lacunar state: clinicopathologic correlation. Neurology 1990; 40: 897–900
   PubMed Web of Science ®Google Scholar
• Obeso J. A., Grandas F., Vaamonde J. Motor complications associated with chronic levodopa therapy in Parkinson's disease. Neurology 1989; 39: 11–19, suppl 2
   PubMed Web of Science ®Google Scholar
• Pederzoli M., Girotti F., Scigliano G. L-dopa long term treatment in Parkinson's disease: age related side effects. Neurology 1983; 33: 1518–1522
   PubMed Web of Science ®Google Scholar
• Podolsky S., Leopold N. A., Sax D. S. Increased frequency of diabetes mellitus in patients with Huntington's chorea. Lancet 1972; 1: 1356–59
   PubMed Web of Science ®Google Scholar
• Said G., Bathien N., Cesaro P. Peripheral neuropathies and tremor. Neurology 1982; 32: 480–485
   PubMedGoogle Scholar
• Saller C. F., Chiodo L. A. Glucose suppresses basal firing and haloperidol increases in the firing rate of central dopaminergic neurons. Science 1980; 210: 1269–1271
   PubMedGoogle Scholar
• Saller C. F., Kopin I. J. Glucose potentiates haloperidol-induced catalepsy. Life Sciences 1981; 29: 2337–2341
   PubMedGoogle Scholar
• Sandyk R. Dopamine and insulin interact to modulate in vitro glucose transport in rat adipocytes. International Journal of Neuroscience 1984; 43: 9–14
   Google Scholar
• Sandyk R. Increased incidence of neuroleptic-induced perioral movements in the rat by hyperglycemia. International of Journal of Neuroscience 1990; 50: 227–232
   PubMed Web of Science ®Google Scholar
• Sandyk R., Awerbuch G. J. Diabetes mellitus and dementia of Parkinson's disease. International Journal of Neuroscience, in press
   Google Scholar
• Sandyk R., Gillman M. A. Tardive dyskinesia and glucose metabolism. Archives of General Psychiatry 1986; 43: 192–193
   PubMedGoogle Scholar
• Sandyk R., Iacono R. P., Bamford C. R. The hypothalamus in Parkinson disease. Italian Journal of Neurological Sciences 1987; 8: 217–234
   Google Scholar
• Sandyk R., Kay S. R., Awerbuch G. I., Iacono R. P. Risk factors for neuroleptic induced movement disorders. International Journal of Neuroscience 1991; 61: 149–188
   PubMed Web of Science ®Google Scholar
• Seeman P. Tardive dyskinesia, dopamine receptors and neuroleptic damage to cell membranes. Journal of Clinical Psychopharmacology 1988; 8: 3S–9S
   PubMedGoogle Scholar
• Singh S., Sandyk R., Kay S. R. Diabetes mellitus as a risk factor for neuroleptic-induced akathisia. Neurology 1990; 40: 146, suppl
   Google Scholar
• Sirtori C. R., Bolme P., Azarnoff D. L. Metabolic responses to acute and chronic L-dopa administration in patients with Parkinsonism. New England Journal of Medicine 1972; 287: 729–733
   PubMed Web of Science ®Google Scholar
• Thornburg J. E., Moore K. E. The relative importance of doparminergic and noradrenergic neuronal systems for the stimulation of locomotor activity induced by amphetamine and other drugs. Neuropharmacology 1973; 12: 853–866
   PubMed Web of Science ®Google Scholar
• Tolosa E. S., Santamaria J. Parkinsonism and basal ganglia infarcts. Neurology 1984; 34: 1516–1518
   PubMed Web of Science ®Google Scholar
• Trulson M. E., Himmel C. D. Decreased brain dopamine synthesis rate and increased (H) spiperidol binding in streptozotocin-diabetic rats. Journal of Neurochemistry 1983; 40: 1456–1459
   PubMedGoogle Scholar
• Trulson M. K., Jacoby J. H., MacKenzie R. G. Streprozocin-induced diabetes reduces brain serotonin synthesis in rats. Journal of Neurochemistry 1986; 46: 1068–1072
   PubMed Web of Science ®Google Scholar
• Wurtman R. J., Larin F., Mostafapour S., Fernstrom J. D. Brain catechol synthesis: control by brain tyrosine concentration. Science 1974; 185: 183–184
   PubMed Web of Science ®Google Scholar
• Van Woert M. H., Mueller P. S. Glucose, insulin, and free fatty acid metabolism in Parkinson's disease treated with levodopa. Clinical Pharmacology & Therapeutics 1971; 12: 360–367
   PubMedGoogle Scholar